In the first quarter, major US managed care insurers reported earnings that exceeded expectations, leading to stock price increases and raised full-year earnings forecasts. The Centers for Medicare & Medicaid Services announced higher-than-expected 2027 Medicare Advantage plan rates, easing investor concerns. Following these developments, several insurers raised their 2024 earnings outlooks. Although Humana Inc. did not raise its 2026 earnings forecast, it still experienced notable stock gains due to the CMS rate increase. These positive trends suggest a strong outlook for the managed care sector moving forward.
Deutsche Bank upgraded Humana from Hold to Buy, raising its price target from $235 to $441, signaling confidence in a recovery driven by stabilizing managed care and improving Medicare star ratings. Mizuho also raised its target to $335, citing a mor...
Humana's stock has surged 48% over the past month, outperforming peers like UnitedHealth and Cigna, driven by strong Medicare Advantage (MA) growth and favorable regulatory decisions. The company reported Q1 2026 adjusted EPS of $10.31, beating estim...
Humana Inc. has been upgraded to a Buy rating following a rebound from a more than 65% stock decline. The upgrade is supported by improved CMS rate decisions and activist investor involvement. Despite 2026 earnings per share guidance being below Q1 l...
